Jann, Johann-Christoph http://orcid.org/0000-0003-2200-0151
Hergott, Christopher B.
Winkler, Marisa
Liu, Yiwen
Braun, Benjamin http://orcid.org/0009-0009-7930-2610
Charles, Anne
Copson, Kevin M.
Barua, Shougat
Meggendorfer, Manja
Nadarajah, Niroshan
Shimony, Shai http://orcid.org/0000-0001-7245-9652
Winer, Eric S.
Wadleigh, Martha
Stone, Richard M. http://orcid.org/0000-0002-7526-2633
DeAngelo, Daniel J. http://orcid.org/0000-0001-7865-2306
Garcia, Jacqueline S. http://orcid.org/0000-0003-2118-6302
Haferlach, Torsten
Lindsley, R. Coleman
Luskin, Marlise R. http://orcid.org/0000-0002-5781-4529
Stahl, Maximilian
Tothova, Zuzana http://orcid.org/0000-0001-6668-532X
Funding for this research was provided by:
Edward P. Evans Foundation
Leukemia and Lymphoma Society
Burroughs Wellcome Fund
Doris Duke Charitable Foundation
Gabrielle's Angel Foundation for Cancer Research
Leukemia and Lymphoma Society
Article History
Received: 21 February 2024
Revised: 7 July 2024
Accepted: 9 July 2024
First Online: 20 July 2024
Competing interests
: JSG is on the Scientific Advisory Board of AbbVie, Astellas, BMS, Genentech, and Servier, and has received institutional funding support for trials from AbbVie, AstraZeneca, Pfizer, Prelude, and Genentech, all unrelated to the current manuscript. MS served on the advisory board for Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi and Syndax; consulted for Boston Consulting and Dedham group and participated in CME activity for Novartis, Curis Oncology, Haymarket Media and Clinical Care Options, all unrelated to this work. ZT has received research funding from Novartis, unrelated to this work.
: All patients gave their informed consent for clinical genetic analyses and the use of laboratory results for research purposes. The study was approved by the DFCI Institutional Review Board (IRB) and the MLL IRB. Research involving human data is in accordance with the Declaration of Helsinki.